Compare Incyte Corporation (INCY) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Jones Lang LaSalle Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Jones Lang LaSalle Inc trades at $362.41 (market cap $16.72B). The key difference: Incyte Corporation is the larger of the two by market cap. Which is the better fit depends on your goals.
| INCY | JLL | |
|---|---|---|
Market Cap | $24.54B | $16.72B |
Sector | Health | Real Estate |
52-Week High | $129.93 | $373.24 |
52-Week Low | $81.61 | $280.16 |
Enterprise Value | $20.04B | $19.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
JLL trades at $362.74, up 1.51% today and near its 52-week high, with a bullish technical signal supported by a golden cross. The company reported strong Q2 2026 earnings, beating estimates with EPS of $5.26 versus $4.56 expected, driven by leasing and capital markets growth. Revenue reached $26.12B in 2025, with net income margin improving to 3.64%. Operating cash flow surged to $1.19B in 2025, reflecting robust financial health. Analyst consensus is a Buy with a $391.50 price target, indicating potential upside from current levels.
The outlook for JLL remains positive given consistent earnings beats, revenue growth, and strong cash flow generation. Key opportunities include momentum in advisory services and recurring revenue streams. Risks involve economic sensitivity to real estate cycles and competitive pressures. Institutional interest is solid, with firms like Bank of America increasing holdings. The stock's valuation at a P/E of 17.43 appears reasonable relative to growth prospects, supporting a constructive view for investors seeking exposure to commercial real estate services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
